期刊文献+

药事立法监管研究领域的学科构成 被引量:2

Disciplinary Structure of the Academic Field of Drug Legislation and Regulation Research
下载PDF
导出
摘要 药事的立法和监管是当今世界各国普遍关注的热点问题,围绕着这个主题的研究已经形成了一个具有相当规模的学术领域。我们从MedLine数据库中检索得到刊载该领域文献的期刊1000多种,根据每种期刊配置的MeSH主题词确定这些期刊的学科归属,在此基础上对该领域的学科构成进行了量化描述。 The intellectual efforts around the issue of concerned about at present have formed an academic scientometric investigation of this academic field drug legislation and regulation that people all over the world are field of a certain scale in amount of publication. This paper is a The authors search MedLine, a major bibliographic database in biomedical research and collect records of more than one thousand magazines each publishing at least one research pa- pers focused on drug legislation and regulation. The discipline(s) to which each journal belongs to be decided, in the light of the MeSH terms assigned to the journal. Based on the amount of journals in every discipline, a quantitative outline is drawn on the disciplinary structure of the field of drug legislation and regulation research.
出处 《科学学与科学技术管理》 CSSCI 北大核心 2008年第7期48-53,共6页 Science of Science and Management of S.& T.
基金 国家自然科学基金项目(70673019)
关键词 药事立法监管研究领域 学科构成 科学计量学 MEDLINE数据库 MESH academic field of Drug Legislation and Regulation Research disciplinmy structure scientometrics: MedLine Database MeSH
  • 相关文献

参考文献5

  • 1MedLine数据库http://www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed.
  • 2黄宇烽.美国MEDLINE概述及向MEDLINE源期刊投稿应注意的问题[J].中华男科学杂志,2006,12(6):483-485. 被引量:9
  • 3Maria, Bordons., Garmen, Bravo., Santos, barrigon. Time- traking of the research profile of a drug using bibliometric tools[J]. Journal of the American Society for Information Science and Technology, 2004,55(5): 445-461.
  • 4Sylvaine, le. Minor., Paulette, Dostatni. A bibliometric study of the publications of the French National Institute for Health and Medical Research (INSERM) [J]. Scientometrics, 1991,22(1): 41-63.
  • 5MedLine 数据库 http://www.ncbi.nlm,nih.gov/books/ bv.fcgi?rid=helppubmed.section.pubmedhelp.Search Field_Descrip.

二级参考文献3

共引文献8

同被引文献28

  • 1陈发桂.中国民间组织发展面临的困境及风险控制[J].重庆行政(公共论坛),2008,9(2):81-83. 被引量:2
  • 2刘大洪,李华振.政府失灵语境下的第三部门研究[J].法学评论,2005,23(6):11-16. 被引量:45
  • 3屈卫群,梁炜.CAB收录南京农业大学科技论文的统计与分析[J].农业图书情报学刊,2005,17(11):139-142. 被引量:4
  • 4http:∥www.ncbi.nlm.nih.gov/pubmed[EB].
  • 5Food and Drug Administration,HHS.New drug and biological drugproducts;evidence needed to demonstrate effectiveness of new drugswhen human efficacy studies are not ethical or feasible.Final rule[G].Federal Register.2002 May 31;67(105):37988-98.
  • 6Manchikanti L.Prescription drug abuse:what is being done to addressthis new drug epidemic?Testimony before the Subcommittee on Crim-inal Justice,Drug Policy and Human Resources[J].Pain Physician,2006,9(4):287-321.
  • 7http:∥sinomed.imicams.ac.cn[EB].
  • 8[美]菲利普.希尔茨.保护公众健康--美国食品药品百年监管历程[M].姚明威,译.北京:中国水利水电出版社,2005:34,48,73,77,115,142,273.
  • 9J Roberts.US AIDS activists urge caution on new anti-HIV drugs[J].BMJ,1994,309(6957):757.
  • 10AIDS activists secure approval for human growth hormone(Serostim)[J].Critical Path AIDS Project,1996,(31):34.

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部